Exelixis, Inc. EXEL today reported positive updated interim data from
an ongoing phase 2 trial of cabozantinib in men with metastatic
castration-resistant prostate cancer (CRPC) and bone metastases. These data
confirm cabozantinib's effects on metastatic bone lesions and soft tissue
disease, and demonstrate a positive impact on bone related pain and narcotic
use, as well as biomarkers of bone formation and resorption. Matthew R. Smith,
M.D., Ph.D., Director of the Genitourinary Malignancies Program at the
Massachusetts General Hospital Cancer Center and an investigator on the trial,
presented the data today in an oral session at the American Society of
Clinical Oncology 2012 Annual Meeting (Abstract #4513), which is taking place
in Chicago, Illinois. In addition, preliminary results from an ongoing phase 1
investigator-sponsored trial (IST) designed to determine the lowest effective
dose of cabozantinib for the treatment of men with CRPC and bone metastases
were also presented at the conference. Richard J. Lee, M.D., Ph.D., Assistant
Physician in the Department of Medicine at Massachusetts General Hospital
Cancer Center, and an investigator on the study, presented the data yesterday
in a poster discussion session (Abstract #4566).
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in